News

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other ...
Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Novo Nordisk slides further on US competition, new CEO concerns
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
McDonald’s, Palantir and Novo Nordisk Earnings: What to Watch Next Week
Earnings season marches on, with quarterly results from Berkshire Hathaway, Palantir and McDonald’s among the highlights over ...
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...
Stock Movers: Novo Nordisk, IAG, Campari
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Ozempic maker Novo Nordisk has its worst day since Black Monday
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk: Catch That Falling Knife
Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the ...